A diabetic patient receiving linezolid for a shin soft‑tissue infection now has thrombocytopenia (platelet count 41 × 10⁹/L), anemia (hemoglobin 10 g/dL) and leukopenia (white‑blood‑cell count 2,300/µL). What is the most likely cause and how should the pancytopenia and infection be managed?

Linezolid-Induced Pancytopenia: Immediate Management

Stop linezolid immediately—the pancytopenia (platelets 41,000/µL, hemoglobin 10 g/dL, WBC 2,300/µL) is almost certainly caused by linezolid-induced myelosuppression, which is a well-documented adverse effect requiring prompt discontinuation. 1, 2

Causality Assessment

Linezolid is the definitive cause of this patient's pancytopenia. The FDA label explicitly warns that myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving linezolid, and when linezolid is discontinued, affected hematologic parameters rise toward pretreatment levels. 2

Supporting Evidence for Linezolid as the Culprit:

• Anemia develops in 10–25% of patients treated with linezolid, with incidence rising as duration increases 1
• Thrombocytopenia occurs in 48.4% of patients during linezolid therapy 3
• Pre-existing anemia markedly increases risk of severe linezolid-related anemia 1
• Hematological toxicity can occur quickly after starting treatment and can affect any cell line 1
• The mechanism involves mitochondrial protein synthesis inhibition, leading to suppression across all three blood cell lineages 1, 4

Immediate Management Steps

1. Discontinue Linezolid Now

Discontinuation of linezolid should be considered in patients who develop or have worsening myelosuppression. 2 Given the severity of pancytopenia (platelets <50,000, WBC <3,000), this is not optional—stop the drug immediately. 1

2. Switch Antibiotic Coverage

Since the wound is healthy and responding, transition to an alternative antibiotic that does not cause myelosuppression:

• Vancomycin is the preferred alternative for MRSA coverage in diabetic foot infections 5
• Daptomycin is an acceptable alternative if vancomycin cannot be used 5
• For diabetic foot osteomyelitis, many patients can be switched to oral therapy after initial parenteral treatment with highly bioavailable agents (fluoroquinolones, clindamycin, trimethoprim-sulfamethoxazole) 5

3. Monitor Blood Counts Closely

• Check CBC daily until counts stabilize or begin to recover 1
• Counts should recover spontaneously after drug discontinuation 1
• Recovery typically begins within 12 days after cessation of linezolid 6

4. Assess Infection Risk with Current Counts

With WBC 2,300/µL (likely ANC <1,500/µL), monitor daily for signs of infection including fever, new localizing symptoms, or clinical deterioration. 1

• If WBC drops to 2,000–3,000/µL OR ANC drops to 1,000–1,500/µL: monitor for infection with daily blood counts; counts should recover spontaneously after drug discontinuation 1
• If WBC drops below 2,000/µL OR ANC drops below 1,000/µL: consider hematology consultation and monitor for infection with daily checks 1

5. Platelet Management

With platelets at 41,000/µL, transfusion is not indicated unless active bleeding occurs or urgent surgery is required. 5

• Platelet transfusion threshold is typically <10,000/µL in stable patients without bleeding 5
• Avoid medications that impair platelet function (NSAIDs, aspirin) 5

6. Anemia Management

With hemoglobin 10 g/dL, transfusion is not indicated unless the patient is symptomatic or hemoglobin drops below 7 g/dL. 5

• Red blood cell transfusion may be considered when hemoglobin is below 7 g/dL, or above if symptoms or particular risk factors are present 5
• If transfusion is given, follow with subsequent intravenous iron supplementation 5

Expected Recovery Timeline

• Thrombocytopenia recovery: typically begins within 12 days after linezolid cessation 6
• Anemia recovery: hemoglobin and reticulocyte levels typically rise within 12 days after cessation 6
• Complete recovery: hematologic parameters rise toward pretreatment levels once linezolid is discontinued 2

When to Consult Hematology

Consider hematology consultation if:

• Counts worsen or fail to improve within 2–3 weeks after linezolid discontinuation 1
• Worsening neutropenia (ANC dropping below 1,000) despite drug discontinuation 1
• Any uncertainty about alternative causes of pancytopenia 5

Critical Pitfall to Avoid

Do not attribute this anemia to "anemia of chronic disease" from diabetes or infection. In patients receiving prolonged linezolid therapy, anemia is far more likely to be caused by linezolid-induced myelosuppression than by anemia of chronic disease. 1 This is a common error that delays appropriate management.